Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
[INTERVIEW] ABL Bio has grown from go-getter to go-to company
ABL Bio's CEO highlights the company's growth since a $1.06B deal with Sanofi for ABL301, a Parkinson's treatment. ABL Bio now attracts global interest, plans clinical trials for ABL301, ABL101, ABL103, and seeks more licensing deals. The CEO emphasizes the importance of strategic growth and maturity in Korea's biopharmaceutical industry.
New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials
Sanofi and GSK's Vidprevtyn, a protein subunit Covid-19 vaccine, shows promising phase 3 trial results, with 58% efficacy against symptoms, 75% against moderate/severe disease, and 100% against severe disease. It's effective as a booster, increasing antibodies 18-30 fold. Plans to seek US and EU authorization, with 100 million doses already produced.
Global Peptide Cancer Drug Therapeutics Market Clinical Analysis and Forecast
The global peptide cancer therapeutics market is projected to exceed US$ 20 billion by 2026, driven by the increasing prevalence of cancer and the demand for efficient treatments. Over 150 cancer peptides are in clinical trials, with more than 20 already marketed. Peptides offer advantages like high tissue permeability and the ability to cross the blood-brain barrier, making them effective in cancer management. Major pharmaceutical companies are investing in peptide-based drugs, with strategic alliances and new product launches fueling market growth.
Alloy Therapeutics Introduces New Licensing Model for ATX-Gx Antibody Technology, Collaborates with Sanofi and Takeda to Revolutionize Therapeutic Development
Alloy Therapeutics introduces a new licensing model for its ATX-Gx antibody technology, eliminating annual fees and milestones, enhancing drug discovery. Collaborates with Sanofi on AntiClastic Antisense Platform for CNS targets and with Takeda on iPSC-derived CAR-T/NK platforms, aiming to revolutionize therapeutic development.
Tapping into the drug discovery potential of AI
Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.
The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms
The article reviews COVID-19 vaccines, focusing on mRNA and adenovirus-based vaccines, their mechanisms, advantages, and challenges in achieving herd immunity. It highlights the Oxford/AstraZeneca, Janssen/Johnson & Johnson, and Novavax vaccines, discussing their efficacy, storage, and distribution challenges, especially in low- and middle-income countries.
MAIA Biotechnology Partners with Regeneron for Phase 1/2 Trial Evaluating THIO Followed by Libtayo in Advanced NSCLC Patients
MAIA Biotechnology partners with Regeneron for a Phase 1/2 trial evaluating THIO followed by Libtayo in advanced NSCLC patients. The trial aims to assess safety, efficacy, and immune system activation, potentially transforming cancer treatment by enhancing immunotherapy effectiveness.
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Biologic therapy, including dupilumab, mepolizumab, and omalizumab, offers new treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting T2 inflammation. These biologics show promise in improving symptoms and quality of life, with dupilumab being FDA-approved. Patient selection for biologics considers disease severity, polyp recurrence risk, and cost-effectiveness, alongside patient preferences and goals.
Related Clinical Trials:
Advancements in the co-formulation of biologic therapeutics
Biologic therapeutics, the future of medicine, promise to revolutionize disease treatment by targeting multiple sites with biologics or their combination with small molecules. Despite their potential, challenges in stability, delivery, and manufacturing persist. Advances in co-formulation strategies are crucial for their clinical application, offering enhanced therapeutic efficacy and patient compliance.
How Do Underserved Communities Prefer To Learn About Clinical Trials
Clinical trials are crucial for healthcare advancements, yet underrepresented populations face barriers to participation. Efforts by companies like Sanofi and Eli Lilly aim to enhance diversity. CISCRP's study highlights the importance of clinical research across races, with trust and awareness being key barriers. Supportive services, education, and leveraging technology are essential for increasing participation among underserved communities.
© Copyright 2025. All Rights Reserved by MedPath